Haemonetics
HAE
120.16
-0.21
-0.17%
Haemonetics
US · HAE
#2165 by market cap
Listed 1970
120.16
-0.21
-0.17%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Company notice
Hae In: Report on significant holdings of stocks, etc. (General)OPENDART · 2026/8/24
-
J.P. Morgan Initiates Haemonetics(HAE.US) With Hold Rating, Announces Target Price $125Market Newswire · 2026/11/10
-
Company notice
Haemonetics | 4: Statement of changes in beneficial ownership of securities-Officer Miller Laurie A.SEC · 2025/9/25
-
Rating change
Baird Maintains Haemonetics(HAE.US) With Buy Rating, Raises Target Price to $119Market Newswire · 2026/8/21
-
Barrington Maintains Haemonetics(HAE.US) With Buy Rating, Maintains Target Price $140Market Newswire · 2026/10/26
-
Rating change
Raymond James Maintains Haemonetics(HAE.US) With Buy Rating, Raises Target Price to $125Market Newswire · 2026/9/3
-
A Quick Look at Today's Ratings for Haemonetics(HAE.US), With a Forecast Between $145 to $165Market Newswire · 2026/11/7
-
Rating change
Barrington Maintains Haemonetics(HAE.US) With Buy Rating, Maintains Target Price $118Market Newswire · 2026/10/1
-
Rating change
Citi Maintains Haemonetics(HAE.US) With Buy Rating, Maintains Target Price $123Market Newswire · 2026/9/18
-
Rating change
BTIG Maintains Haemonetics(HAE.US) With Buy Rating, Maintains Target Price $130Market Newswire · 2026/10/20
-
Company notice
Haemonetics | 4: Statement of changes in beneficial ownership of securities-Officer Miller Laurie A.SEC · 2025/6/10
-
Company notice
4: Haemonetics | 4: Statement of changes in beneficial ownership of securities-Officer Miller Laurie A.SEC · 2026/6/9
-
Rating change
Mizuho Securities Maintains Haemonetics(HAE.US) With Buy Rating, Raises Target Price to $140Market Newswire · 2026/10/9
-
Rating change
BTIG Maintains Haemonetics(HAE.US) With Buy Rating, Raises Target Price to $130Market Newswire · 2026/10/8
-
Rating change
Citi Upgrades Haemonetics(HAE.US) to Buy Rating, Raises Target Price to $123Market Newswire · 2026/9/17
-
Company notice
Haemonetics | 4: Statement of changes in beneficial ownership of securities-Officer Miller Laurie A.SEC · 2026/5/20
-
Rating change
BofA Securities Maintains Haemonetics(HAE.US) With Buy Rating, Raises Target Price to $140Market Newswire · 2026/10/9
-
Rating change
Barrington Maintains Haemonetics(HAE.US) With Buy Rating, Raises Target Price to $140Market Newswire · 2026/10/9
-
Jefferies Initiates Haemonetics(HAE.US) With Buy Rating, Announces Target Price $150Market Newswire · 2026/11/13
-
Needham Maintains Haemonetics(HAE.US) With Hold RatingMarket Newswire · 2026/10/22
-
Rating change
Barrington Maintains Haemonetics(HAE.US) With Buy Rating, Raises Target Price to $118Market Newswire · 2026/8/19
-
Rating change
BofA Securities Maintains Haemonetics(HAE.US) With Buy Rating, Raises Target Price to $120Market Newswire · 2026/8/18
-
Rating change
BofA Securities Maintains Haemonetics(HAE.US) With Buy Rating, Maintains Target Price $120Market Newswire · 2026/8/18
-
Rating change
Needham Maintains Haemonetics(HAE.US) With Hold RatingMarket Newswire · 2026/8/18
-
Rating change
Citi Maintains Haemonetics(HAE.US) With Hold Rating, Maintains Target Price $92Market Newswire · 2026/8/13
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Haemonetics discussion 0 comments